461 related articles for article (PubMed ID: 34131808)
1. Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma.
Tuerhong A; Xu J; Shi S; Tan Z; Meng Q; Hua J; Liu J; Zhang B; Wang W; Yu X; Liang C
Cell Mol Life Sci; 2021 Jul; 78(14):5505-5526. PubMed ID: 34131808
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
[TBL] [Abstract][Full Text] [Related]
3. Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy.
Bhoopathi P; Mannangatti P; Das SK; Fisher PB; Emdad L
Adv Cancer Res; 2023; 159():285-341. PubMed ID: 37268399
[TBL] [Abstract][Full Text] [Related]
4. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
[TBL] [Abstract][Full Text] [Related]
5. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions.
Zhang Y; Yang C; Cheng H; Fan Z; Huang Q; Lu Y; Fan K; Luo G; Jin K; Wang Z; Liu C; Yu X
J Hematol Oncol; 2018 Jan; 11(1):14. PubMed ID: 29386069
[TBL] [Abstract][Full Text] [Related]
6. Targeting Pancreatic Ductal Adenocarcinoma (PDAC).
Parrasia S; Zoratti M; Szabò I; Biasutto L
Cell Physiol Biochem; 2021 Jan; 55(1):61-90. PubMed ID: 33508184
[TBL] [Abstract][Full Text] [Related]
7. Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance.
Capula M; Perán M; Xu G; Donati V; Yee D; Gregori A; Assaraf YG; Giovannetti E; Deng D
Drug Resist Updat; 2022 Sep; 64():100864. PubMed ID: 36115181
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitin-specific protease 7 is a druggable target that is essential for pancreatic cancer growth and chemoresistance.
Chen H; Zhu X; Sun R; Ma P; Zhang E; Wang Z; Fan Y; Zhou G; Mao R
Invest New Drugs; 2020 Dec; 38(6):1707-1716. PubMed ID: 32468271
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
10. Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma.
Altan B; Kaira K; Watanabe A; Kubo N; Bao P; Dolgormaa G; Bilguun EO; Araki K; Kanai Y; Yokobori T; Oyama T; Nishiyama M; Kuwano H; Shirabe K
Cancer Chemother Pharmacol; 2018 Jan; 81(1):141-153. PubMed ID: 29149426
[TBL] [Abstract][Full Text] [Related]
11. Cancer-associated fibroblasts in pancreatic adenocarcinoma.
Pan B; Liao Q; Niu Z; Zhou L; Zhao Y
Future Oncol; 2015 Sep; 11(18):2603-10. PubMed ID: 26284509
[TBL] [Abstract][Full Text] [Related]
12. Exploring the therapeutic potential of focal adhesion kinase inhibition in overcoming chemoresistance in pancreatic ductal adenocarcinoma.
Scianò F; Terrana F; Pecoraro C; Parrino B; Cascioferro S; Diana P; Giovannetti E; Carbone D
Future Med Chem; 2024 Feb; 16(3):271-289. PubMed ID: 38269431
[TBL] [Abstract][Full Text] [Related]
13. Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance.
D'Errico G; Alonso-Nocelo M; Vallespinos M; Hermann PC; Alcalá S; García CP; Martin-Hijano L; Valle S; Earl J; Cassiano C; Lombardia L; Feliu J; Monti MC; Seufferlein T; García-Bermejo L; Martinelli P; Carrato A; Sainz B
Oncogene; 2019 Jul; 38(27):5469-5485. PubMed ID: 30936462
[TBL] [Abstract][Full Text] [Related]
14. IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma.
Long KB; Tooker G; Tooker E; Luque SL; Lee JW; Pan X; Beatty GL
Mol Cancer Ther; 2017 Sep; 16(9):1898-1908. PubMed ID: 28611107
[TBL] [Abstract][Full Text] [Related]
15. Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance.
Kaoutari AE; Fraunhoffer NA; Hoare O; Teyssedou C; Soubeyran P; Gayet O; Roques J; Lomberk G; Urrutia R; Dusetti N; Iovanna J
EBioMedicine; 2021 Apr; 66():103332. PubMed ID: 33862584
[TBL] [Abstract][Full Text] [Related]
16. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y
Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of glycolysis-related prognostic score for prediction of prognosis and chemosensitivity of pancreatic ductal adenocarcinoma.
Zhang XP; Chen Q; Liu Q; Wang Y; Wang F; Zhao ZM; Zhao GD; Lau WY; Gao YZ; Liu R
J Cell Mol Med; 2021 Jun; 25(12):5615-5627. PubMed ID: 33942483
[TBL] [Abstract][Full Text] [Related]
19. Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines.
Braun LM; Lagies S; Guenzle J; Fichtner-Feigl S; Wittel UA; Kammerer B
Cells; 2020 May; 9(5):. PubMed ID: 32438599
[TBL] [Abstract][Full Text] [Related]
20. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
